source
- AbCellera's Phase 2 hot flash trial beats aggressive upside target, challenging Astellas and BayerAbCellera announced that its Phase 2 study of ABCL635, an antibody that blocks the NK3R receptor, met its primary endpoint in postmenopausal women with hot flashes. The trial enrolled 92 participan…
- FDA advisory panel set to review Grail’s multi-cancer Galleri screening testAn FDA advisory committee is scheduled to evaluate Grail’s Galleri blood test, which is designed to detect a range of cancers at an early stage. The panel will examine the test’s clinical data, pe…